Evidence map›Paper›PMID 38499449›Full record

ArticleJournal of inherited metabolic disease2024

T cell activation contributes to purifying selection against the MELAS-associated m.3243A>G pathogenic variant in blood.

Melissa A Walker, Shuqiang Li, Kenneth J Livak, Amel Karaa, Catherine J Wu, Vamsi K Mootha

Abstract read
In one paragraph

Article in Journal of inherited metabolic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Melissa A WalkerDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-7423-9538
Shuqiang LiBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Kenneth J LivakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Amel KaraaDepartment of Pediatrics, Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Catherine J WuBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Vamsi K MoothaHoward Hughes Medical Institute and the Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Funding

Cancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4M
Single cell investigation of co-evolution in cancer cells and host cell immune microenvironmentR50CA251956 · NCI · DANA-FARBER CANCER INST · PI Shuqiang Li · 2020 to 2026
$1.4M
Dual Genome Omics: Adapting Genomics Techniques to Reveal Molecular Pathology in Mitochondrial DiseaseK08NS117889 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, MELISSA ANNE · 2021 to 2025
$1.0M
Howard Hughes Medical InstituteJ. Willard and Alice S. Marriott FoundationMacCurtain FamilyNCI NIH HHS R50 CA251956NCI NIH HHS U24 CA224331NCI Research Specialist Award R50CA251956NIH HHSNIH/NCI 2U24CA224331-02NINDS NIH HHS K08 NS117889NINDS NIH HHS K08NS117889
6 · The paper itself

Abstract

T cells have been shown to maintain a lower percentage (heteroplasmy) of the pathogenic m.3243A>G variant (MT-TL1, associated with maternally inherited diabetes and deafness [MIDD] and mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes [MELAS]). The mechanism(s) underlying this purifying selection, however, remain unknown. Here we report that purified patient memory CD4+ T cells have lower bulk m.3243A>G heteroplasmy compared to naïve CD4+ T cells. In vitro activation of naïve CD4+ m.3243A>G patient T cells results in lower bulk m.3243A>G heteroplasmy after proliferation. Finally, m.3243A>G patient T cell receptor repertoire sequencing reveals relative oligoclonality compared to controls. These data support a role for T cell activation in peripheral, purifying selection against high m.3243A>G heteroplasmy T cells at the level of the cell, in a likely cell-autonomous fashion.

Indexed as

Lymphocyte ActivationMELAS SyndromeAdultCD4-Positive T-LymphocytesDNA, MitochondrialFemaleHeteroplasmyHumansMaleRNA, Transfer, LeuDNA, MitochondrialMT-TL1 tRNA, humanRNA, Transfer, LeuheteroplasmyMELASMIDDmitochondriamtDNAT cell activation

Identifiers

PMID38499449
PMCPMC11251844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.